Interrupted time series analysis on first cardiovascular disease hospitalization for adherence to lipid-lowering therapy.
cardiovascular diseases
interrupted time series analysis
medication adherence
pharmacoepidemiology
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
14
05
2019
revised:
04
10
2019
accepted:
11
10
2019
pubmed:
4
12
2019
medline:
23
1
2021
entrez:
3
12
2019
Statut:
ppublish
Résumé
We analysed lipid-lowering medication adherence before and after the first hospitalization for cardiovascular disease (CVD) to explore the influence hospitalization has on patient medication adherence. We extracted a sub-cohort for analysis from 313,207 patients who had primary CVD risk assessment. Adherence was assessed as proportion of days covered (PDC) ≥ 80% based on community dispensing records. Adherence in the 4 quarters (360 days) before the first CVD hospitalization and 8 quarters (720 days) after hospital discharge was assessed for each individual in the sub-cohort. An interrupted time series design using generalized estimating equations was applied to compare the differences of population-level medication adherence rates before and after the first CVD hospitalization. Overall, a significant improvement in medication adherence rate from before to after the hospitalization was observed (odds ratio (OR) 2.49 [1.74-3.57]) among the 946 patients included in the analysis. Patients having diabetes history had a higher OR of adherence before the hospitalization than patients without diabetes (1.50 [1.03-2.22]) but no significant difference after the hospitalization (OR 1.13 [0.89-1.43]). Before the first hospitalization, we observed that quarterly medication adherence rate was steady at around 55% (OR 0.97 [0.93-1.01), whereas the trend in adherence over the post-hospitalization period decreased significantly per quarter (OR 0.97 [0.94-0.99]). Patients were more likely to adhere to lipid-lowering therapy after experiencing a first CVD hospitalization. The change in medication adherence rate is consistent with patients having heightened perception of disease severity following the hospitalization.
Substances chimiques
Hypolipidemic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
150-160Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
World Health Organization. Cardiovascular diseases (CVDs). 2019. Available at: https://www.who.int/cardiovascular_diseases/en/.
Stewart J, Manmathan G, Wilkinson P. Primary prevention of cardiovascular disease: A review of contemporary guidance and literature. JRSM Cardiovasc Dis. 2017;6:1-9. https://doi.org/10.1177/2048004016687211
Lindenauer. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. JAMA. 2004;291(17):2092-2099. Available at:. https://doi.org/10.1001/jama.291.17.2092
Cholesterol Treatment Trialists. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278. https://doi.org/10.1016/S0140-6736(05)67394-1
Kolandaivelu K, Leiden BB, O'Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J. 2014;35(46):3267-3276. https://doi.org/10.1093/eurheartj/ehu364
Julius RJD, Novitsky MAJ, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract. 2009;15(1):34-44. https://doi.org/10.1097/01.pra.0000344917.43780.77
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: Its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-3035. https://doi.org/10.1161/CIRCULATIONAHA.108.768986
Ismail LMN, Selim MA-A, Elkhashab SOY. Factors affecting medication adherence among patients with rheumatic disorders. J Nurs Educ Pract. 2017;7:7-18. https://doi.org/10.5430/jnep.v7n8p7
Warren JR, Falster MO, Fox D, Jorm L. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf. 2013;22(12):1298-1307. https://doi.org/10.1002/pds.3526
Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: Findings from a large pharmacy claims database. Diabetes Care. 2015;38(4):604-609. https://doi.org/10.2337/dc14-2098
McKenzie SJ, McLaughlin D, Clark J, Doi SAR. The Burden of Non-Adherence to Cardiovascular Medications Among the Aging Population in Australia: A Meta-Analysis. Drugs Aging. 2015;32(3):217-225. https://doi.org/10.1007/s40266-015-0245-1
Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med. 2004;19(6):638-645. https://doi.org/10.1111/j.1525-1497.2004.30516.x
Aggarwal B, Mosca L. Lifestyle and psychosocial risk factors predict non-adherence to medication. Ann Behav Med. 2010;40(2):228-233. https://doi.org/10.1007/s12160-010-9212-6
Erickson SR, Lin Y-NT. Geospatial analysis of statin adherence using pharmacy claims data in the State of Michigan. J Manag Care Pharm. 2014;20:1208-1215. https://doi.org/10.18553/jmcp.2014.20.12.1208
Hoang C, Kolenic G, Kline-Rogers E, Eagle KA, Erickson SR. Mapping geographic areas of high and low drug adherence in patients prescribed continuing treatment for acute coronary syndrome after discharge. Pharmacotherapy. 2011;31(10):927-933. https://doi.org/10.1592/phco.31.10.927
Hu F, Warren J, Exeter DJ. Geography and patient history in long-term lipid lowering medication adherence for primary prevention of cardiovascular disease. Spat Spatiotemporal Epidemiol. 2019;29:13-29. https://doi.org/10.1016/j.sste.2018.12.001
Molfenter TD, Bhattacharya A, Gustafson DH. The roles of past behavior and health beliefs in predicting medication adherence to a statin regimen. Patient Prefer Adherence. 2012;6:643-651. https://doi.org/10.2147/PPA.S34711
Franklin JM, Shrank WH, Lii J, et al. Observing versus predicting: Initial patterns of filling predict long-term adherence more accurately than high-dimensional modeling techniques. Health Serv Res. 2016;51(1):220-239. https://doi.org/10.1111/1475-6773.12310
Haskard-Zolnierek KB, DiMatteo MR. Physician Communication and Patient Adherence to Treatment: A Meta-analysis. Med Care. 2009;47(8):826-834. https://doi.org/10.1097/MLR.0b013e31819a5acc
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304-314. https://doi.org/10.4065/mcp.2010.0575
Halava H, Westerlund H, Korhonen MJ, et al. Influence of retirement on adherence to statins in the insurance medicine all-Sweden total population data base. PLoS One. 2015;10:1-14. https://doi.org/10.1371/journal.pone.0130901
Kivimäki M, David Batty G, Hamer M, et al. Influence of retirement on nonadherence to medication for hypertension and diabetes. Can Med Assoc J. 2013;185(17):784-790. https://doi.org/10.1503/cmaj.122010
Amin K, Farley JF, Maciejewski ML, Domino ME. Effect of Medicaid Policy Changes on Medication Adherence: Differences by Baseline Adherence. J Manag Care Spec Pharm. 2017;23:337-345. https://doi.org/10.18553/jmcp.2017.23.3.337
Wang V, Liu C-F, Bryson CL, Sharp ND, Maciejewski ML. Does Medication Adherence Following a Copayment Increase Differ by Disease Burden? Health Serv Res. 2011;46(6pt1):1963-1985. https://doi.org/10.1111/j.1475-6773.2011.01286.x
Zanders MMJ, Haak HR, van Herk-Sukel MPP, van de Poll-Franse LV, Johnson JA. Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia. 2015;58(5):951-960. https://doi.org/10.1007/s00125-015-3497-8
Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM. Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf. 2015;24(1):75-85. https://doi.org/10.1002/pds.3660
Weinman J, Petrie KJ, Sharpe N, Walker S. Causal attributions in patients and spouses following first-time myocardial infarction and subsequent lifestyle changes. Br J Health Psychol. 2000;5:263-273. https://doi.org/10.1348/135910700168900
Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: Patient beliefs and health-related behaviour. J Psychosom Res. 2005;58(5):403-415. https://doi.org/10.1016/j.jpsychores.2004.11.010
Phatak HM, Joseph Thomas III. Relationships Between Beliefs about Medications and Nonadherence to Prescribed Chronic Medications. Ann Pharmacother. 2006;40(10):1737-1742. https://doi.org/10.1345/aph.1H153
Mojtabai R, Olfson M. Medication costs, adherence, and health outcomes among medicare beneficiaries. Health Aff. 2003;22(4):220-229. https://doi.org/10.1080/0161956X.2016.1151741
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater Adherence To Diabetes Drugs Is Linked To Less Hospital Use And Could Save Nearly $5 Billion Annually. Health Aff. 2012;31(8):1836-1846. https://doi.org/10.1377/hlthaff.2011.1198
Beloin-Jubinville B, Joly-Mischlich T, Dufort Rouleau E, et al. Does hospitalization influence patients' medication adherence and community pharmacists' interventions? Ann Pharmacother. 2013;47(9):1143-1152. https://doi.org/10.1177/1060028013503123
Kronish IM, Ross JS, Zhao H, Muntner P. Impact of hospitalization for acute myocardial infarction on adherence to statins among older adults. Circ Cardiovasc Qual Outcomes. 2016;9(4):364-371. https://doi.org/10.1161/CIRCOUTCOMES.115.002418
de Vries FM, Denig P, Vegter S, Bos HJ, Postma MJ, Hak E. Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design. Curr Med Res Opin. 2015;31:595-602. https://doi.org/10.1185/03007995.2015.1011780
Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: A tutorial. Int J Epidemiol. 2017;46(1):348-355. https://doi.org/10.1093/ije/dyw098
Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299-309. https://doi.org/10.1046/j.1365-2710.2002.00430.x
Geue C, Lewsey JD, MacKay DF, et al. Scottish Keep Well health check programme: An interrupted time series analysis. J Epidemiol Community Health. 2016;70(9):924-929. https://doi.org/10.1136/jech-2015-206926
Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med. 2006;174:710-716. https://doi.org/10.1164/rccm.200603-432OC
Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: Interrupted time series analysis with UK primary care data. BMJ. 2016;353:1-10. https://doi.org/10.1136/bmj.i3283
Wells S, Furness S, Rafter N, et al. Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice. Eur J Prev Cardiol. 2008;15:173-178. https://doi.org/10.1097/HJR.0b013e3282f13af4
Wells S, Riddell T, Kerr A, et al. Cohort Profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). Int J Epidemiol 2017; 46: 22-22j. https://doi.org/10.1093/ije/dyv312.
Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet. 2018;391(10133):1897-1907. https://doi.org/10.1016/S0140-6736(18)30664-0
Salmond C, Crampton P, Atkinson J. NZDep2006 Index of Deprivation. Department of Public Health, University of Otago Wellington, 2007. Available at: http://www.otago.ac.nz/wellington/otago020348.pdf.
Atkinson J, Salmond C, Crampton P. NZDep2013 Index of Deprivation. Department of Public Health, University of Otago Wellington, 2014. Available at: https://www.otago.ac.nz/wellington/departments/publichealth/research/hirp/otago020194.html.
New Zealand Ministry of Health. Ethnicity Data Protocols for the Health and Disability Sector. Wellington: Ministry of Health, 2004. ISBN 0-478-25846-1.
Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565-574. https://doi.org/10.1002/pds.1230
Kripalani S, Goggins K, Nwosu S, et al. Medication Nonadherence before Hospitalization for Acute Cardiac Events. J Health Commun. 2015;20:34-42. https://doi.org/10.1080/10810730.2015.1080331
Grey C, Jackson R, Wells S, et al. Maintenance of statin use over 3 years following acute coronary syndromes: A national data linkage study (ANZACS-QI-2). Heart. 2014;100(10):770-774. https://doi.org/10.1136/heartjnl-2013-304960
Mabotuwana T, Warren J, Harrison J, Kenealy T. What can primary care prescribing data tell us about individual adherence to long-term medication?-comparison to pharmacy dispensing data. Pharmacoepidemiol Drug Saf. 2009;18(10):956-964. https://doi.org/10.1002/pds.1803
Gu Y, Warren J, Kennelly J, Neuwelt P, Harwood M. Cardiovascular disease risk management for Maori in New Zealand general practice. J Prim Health Care. 2014;6(4):286-294. Available at:. http://www.publish.csiro.au/HC/HC14286
Charles H, Good CB, Hanusa BH, Chang C-CH, Whittle J. Racial differences in adherence to cardiac medications. J Natl Med Assoc. 2003;95(1):17-27. Available at:. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2594358/pdf/jnma00305-0038.pdf
Traylor AH, Schmittdiel JA, Uratsu CS, Mangione CM, Subramanian U. Adherence to cardiovascular disease medications: Does patient-provider race/ethnicity and language concordance matter? J Gen Intern Med. 2010;25(11):1172-1177. https://doi.org/10.1007/s11606-010-1424-8
Davis SK, Liu Y, Gibbons GH. Disparities in trends of hospitalization for potentially preventable chronic conditions among African Americans during the 1990s: Implications and benchmarks. Am J Public Health. 2003;93(3):447-455. https://doi.org/10.2105/AJPH.93.3.447
Slejko JF, Ho M, Anderson HD, Nair KV, Sullivan PW, Campbell JD. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm. 2014;20(1):51-57.
Bi Y, Gao R, Patel A, et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: Results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J 2009; 157: 509-516.e1. doi:https://doi.org/10.1016/j.ahj.2008.09.026.
Kassab YW, Hassan Y, Aziz NA, Zulkifly HH, Iqbal MS. Report: Trends in adherence to secondary prevention medications in post-acute coronary syndrome patients. Pak J Pharm Sci. 2015;28(2):641-646. https://doi.org/10.1021/acs.chemmater.6b01729
Glader EL, Sjölander M, Eriksson M, Lundberg M. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke. 2010;41(2):397-401. https://doi.org/10.1161/STROKEAHA.109.566950
Yang S, He C, Zhang X, et al. Determinants of antihypertensive adherence among patients in Beijing: Application of the health belief model. Patient Educ Couns. 2016;99(11):1894-1900. https://doi.org/10.1016/j.pec.2016.06.014
Heydari H, Kamran A, Ss A, Biria M, Malepour A. Determinants of patient′s adherence to hypertension medications: Application of health belief model among rural patients. Ann Med Health Sci Res. 2014;4(6):922-927. https://doi.org/10.4103/2141-9248.144914
Alatawi YM, Kavookjian J, Ekong G, Alrayees MM. The association between health beliefs and medication adherence among patients with type 2 diabetes. Res Soc Adm Pharm. 2016;12(6):914-925. https://doi.org/10.1016/j.sapharm.2015.11.006
Daniel M, Messer LC. Perceptions of disease severity and barriers to self-care predict glycemic control in aboriginal persons with type 2 diabetes mellitus. Chronic Dis Can. 2002;23(4):130-138.
Hawkins LA, Kilian S, Firek A, Kashner TM, Firek CJ, Silvet H. Cognitive impairment and medication adherence in outpatients with heart failure. Hear Lung. 2012;41:572-582. https://doi.org/10.1016/j.hrtlng.2012.06.001